Comprehensive validation of array comparative genomic hybridization platforms: How much is enough?

Erik C Thorland, Patrick R. Gonzales, Troy J. Gliem, Anne E. Wiktor, Rhett P. Ketterling

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Clinical testing using various array comparative genomic hybridization platforms is being incorporated rapidly into cytogenetic testing algorithms. Comprehensive validation of these complex assays presents unique challenges and very few studies reporting the validation of commercially available array platforms have been published. Sixty-seven patients with previously defined subtelomere abnormalities, representing deletions and/or duplications of all 41 clinically relevant sites, were tested in a blinded study using the Spectral Genomics Constitutional Chip 3.0. Overall, 72 of 74 (97%) subtelomeric abnormalities were concordant with previous cytogenetic studies. However, two false-negative results were documented, and issues with mismapped and suboptimal clone performance were identified that may result in failure to detect 6q and 20q subtelomeric abnormalities. The results of this study indicate that comprehensive validation is necessary before implementation of array comparative genomic hybridization platforms into a clinical setting. Specific suggestions for validation are discussed in the context of the recently proposed American College of Medical Genetics guidelines for microarray analysis for constitutional cytogenetic abnormalities.

Original languageEnglish (US)
Pages (from-to)632-641
Number of pages10
JournalGenetics in Medicine
Volume9
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Comparative Genomic Hybridization
Cytogenetics
Validation Studies
Microarray Analysis
Genomics
Chromosome Aberrations
Clone Cells
Guidelines

Keywords

  • Array CGH
  • Array comparative genomic hybridization
  • Microarray validation
  • Subtelomeric abnormalities

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Comprehensive validation of array comparative genomic hybridization platforms : How much is enough? / Thorland, Erik C; Gonzales, Patrick R.; Gliem, Troy J.; Wiktor, Anne E.; Ketterling, Rhett P.

In: Genetics in Medicine, Vol. 9, No. 9, 09.2007, p. 632-641.

Research output: Contribution to journalArticle

Thorland, Erik C ; Gonzales, Patrick R. ; Gliem, Troy J. ; Wiktor, Anne E. ; Ketterling, Rhett P. / Comprehensive validation of array comparative genomic hybridization platforms : How much is enough?. In: Genetics in Medicine. 2007 ; Vol. 9, No. 9. pp. 632-641.
@article{ba08f095b0c94b64af9fdb60cb37877b,
title = "Comprehensive validation of array comparative genomic hybridization platforms: How much is enough?",
abstract = "Clinical testing using various array comparative genomic hybridization platforms is being incorporated rapidly into cytogenetic testing algorithms. Comprehensive validation of these complex assays presents unique challenges and very few studies reporting the validation of commercially available array platforms have been published. Sixty-seven patients with previously defined subtelomere abnormalities, representing deletions and/or duplications of all 41 clinically relevant sites, were tested in a blinded study using the Spectral Genomics Constitutional Chip 3.0. Overall, 72 of 74 (97{\%}) subtelomeric abnormalities were concordant with previous cytogenetic studies. However, two false-negative results were documented, and issues with mismapped and suboptimal clone performance were identified that may result in failure to detect 6q and 20q subtelomeric abnormalities. The results of this study indicate that comprehensive validation is necessary before implementation of array comparative genomic hybridization platforms into a clinical setting. Specific suggestions for validation are discussed in the context of the recently proposed American College of Medical Genetics guidelines for microarray analysis for constitutional cytogenetic abnormalities.",
keywords = "Array CGH, Array comparative genomic hybridization, Microarray validation, Subtelomeric abnormalities",
author = "Thorland, {Erik C} and Gonzales, {Patrick R.} and Gliem, {Troy J.} and Wiktor, {Anne E.} and Ketterling, {Rhett P.}",
year = "2007",
month = "9",
doi = "10.1097/GIM.0b013e31814629fc",
language = "English (US)",
volume = "9",
pages = "632--641",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Comprehensive validation of array comparative genomic hybridization platforms

T2 - How much is enough?

AU - Thorland, Erik C

AU - Gonzales, Patrick R.

AU - Gliem, Troy J.

AU - Wiktor, Anne E.

AU - Ketterling, Rhett P.

PY - 2007/9

Y1 - 2007/9

N2 - Clinical testing using various array comparative genomic hybridization platforms is being incorporated rapidly into cytogenetic testing algorithms. Comprehensive validation of these complex assays presents unique challenges and very few studies reporting the validation of commercially available array platforms have been published. Sixty-seven patients with previously defined subtelomere abnormalities, representing deletions and/or duplications of all 41 clinically relevant sites, were tested in a blinded study using the Spectral Genomics Constitutional Chip 3.0. Overall, 72 of 74 (97%) subtelomeric abnormalities were concordant with previous cytogenetic studies. However, two false-negative results were documented, and issues with mismapped and suboptimal clone performance were identified that may result in failure to detect 6q and 20q subtelomeric abnormalities. The results of this study indicate that comprehensive validation is necessary before implementation of array comparative genomic hybridization platforms into a clinical setting. Specific suggestions for validation are discussed in the context of the recently proposed American College of Medical Genetics guidelines for microarray analysis for constitutional cytogenetic abnormalities.

AB - Clinical testing using various array comparative genomic hybridization platforms is being incorporated rapidly into cytogenetic testing algorithms. Comprehensive validation of these complex assays presents unique challenges and very few studies reporting the validation of commercially available array platforms have been published. Sixty-seven patients with previously defined subtelomere abnormalities, representing deletions and/or duplications of all 41 clinically relevant sites, were tested in a blinded study using the Spectral Genomics Constitutional Chip 3.0. Overall, 72 of 74 (97%) subtelomeric abnormalities were concordant with previous cytogenetic studies. However, two false-negative results were documented, and issues with mismapped and suboptimal clone performance were identified that may result in failure to detect 6q and 20q subtelomeric abnormalities. The results of this study indicate that comprehensive validation is necessary before implementation of array comparative genomic hybridization platforms into a clinical setting. Specific suggestions for validation are discussed in the context of the recently proposed American College of Medical Genetics guidelines for microarray analysis for constitutional cytogenetic abnormalities.

KW - Array CGH

KW - Array comparative genomic hybridization

KW - Microarray validation

KW - Subtelomeric abnormalities

UR - http://www.scopus.com/inward/record.url?scp=34548661037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548661037&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e31814629fc

DO - 10.1097/GIM.0b013e31814629fc

M3 - Article

C2 - 17873652

AN - SCOPUS:34548661037

VL - 9

SP - 632

EP - 641

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 9

ER -